Metabolism - Clinical and Experimental
Volume 55, Issue 7 , Pages 972-979 , July 2006

Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia

  • Thomas Dayspring

      Affiliations

    • North Jersey Institute of Menopausal Lipidology, Wayne, NJ 07470, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 973 790 8604; fax: +1 973 790 1488.
    • ,
  • Yongming Qu

      Affiliations

    • Women's Health and Reproductive Medicine, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    • ,
  • Cheryl Keech

      Affiliations

    • Women's Health and Reproductive Medicine, Lilly Research Laboratories, Indianapolis, IN 46285, USA

Received 25 May 2005 ,Accepted 1 March 2006.

References 

  1. American Heart Association . 2002 Heart and stroke statistical update. Available at: www.americanheart.org
  2. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–219
  3. Lloyd-Jones DM, O'Donnell CJ, D'Agostino RB, et al. Applicability of cholesterol-lowering primary prevention trials to a general population: the Framingham Heart Study. Arch Intern Med. 2001;161:949–954
  4. Assmann G, Schulte H, Funke H, et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(Suppl M):M8–M14
  5. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B–12B
  6. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991;11:2–14
  7. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  8. Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med. 1995;332:1491–1498
  9. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 1998;81:13B–17B
  10. Dayspring TD. Coronary heart disease in women: triglycerides and lipoprotein biology. J Gend Specif Med. 2002;5:27–33
  11. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–613
  12. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril. 2001;76:13–24
  13. Kuller LH. Hormone replacement therapy and risk of cardiovascular disease: implications of the results of the Women's Health Initiative. Arterioscler Thromb Vasc Biol. 2003;23:11–16
  14. Evista package insert. Indianapolis (Ind): Eli Lilly and Company; 2001;
  15. Mosca L, Harper K, Sarkar S, et al. Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia. Clin Ther. 2001;23:1552–1565
  16. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287:847–857
  17. Moriarty PM. Using both “relative risk reduction” and “number needed to treat” in evaluating primary and secondary clinical trials of lipid reduction. Am J Cardiol. 2001;87:1206–1208
  18. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445–1451
  19. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2000;85:214–218
  20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  21. Davis RA. Cell and molecular biology of the assembly and secretion of apolipoprotein B–containing lipoproteins by the liver. Biochim Biophys Acta. 1999;1440:1–31
  22. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026–2033
  23. Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477–484
  24. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1453–1460
  25. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875–881
  26. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720–732
  27. Cui Y, Blumenthal RS, Flaws JA, et al. Non–high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413–1419
  28. Grundy SM. Low-density lipoprotein, non–high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002;106:2526–2529
  29. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498–511
  30. Insull W, Davidson MH, Kulkarni PM, et al. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism. 2005;54:939–946
  31. Gotto AM. Contemporary diagnosis and management of lipid disorders. Newtown (Pa): Handbooks in Health Care; 1999;
  32. Carr MC, Knopp RH, Brunzell JD, et al. Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy. Diabetes Care. 2005;28:1555–1561
  33. Asztalos BF, Collins D, Cupples LA, et al. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005;25:2185–2191
  34. Knopp RH, Zhu X, Bonet B. Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women. Atherosclerosis. 1994;110(Suppl):S83–S91
  35. Wakatsuki A, Ikenoue N, Izumiya C, et al. Effect of estrogen and simvastatin on low-density lipoprotein subclasses in hypercholesterolemic postmenopausal women. Obstet Gynecol. 1998;92:367–372
  36. Wakatsuki A, Ikenoue N, Okatani Y, et al. Estrogen-induced small low density lipoprotein particles may be atherogenic in postmenopausal women. J Am Coll Cardiol. 2000;37:425–430
  37. Baetta R, Comparato C, Altana C, et al. Raloxifene reduces macrophage accumulation and matrix metalloproteinase expression in carotid lesions of ovariectomized, cholesterol-fed rabbits. Circulation. 2001;104:II-67
  38. Simoncini T, Genazzani AR. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab. 2000;85:2966–2969
  39. Colacurci N, Manzella D, Fornaro F, et al. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab. 2003;88:2135–2140

PII: S0026-0495(06)00103-X

doi: 10.1016/j.metabol.2006.03.005

Metabolism - Clinical and Experimental
Volume 55, Issue 7 , Pages 972-979 , July 2006

Article Tools

* Image Usage & Resolution